Department of Dermatology, Christian Hospital Unna, Unna, Germany.
Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.
Clin Exp Dermatol. 2022 Mar;47(3):608-609. doi: 10.1111/ced.15018. Epub 2021 Dec 11.
The safety and efficacy of immune checkpoint inhibitors in solid organ transplant recipients (SOTR) are unclear, as SOTR are usually excluded from clinical investigations due to their high risk for irreversible allograft rejection. We observed a kidney transplant patient with metastatic cutaneous squamous cell carcinoma who experienced complete response under anti-tumour therapy using cemiplimab and prevention of transplant rejection by fixed dose everolimus.
免疫检查点抑制剂在实体器官移植受者（SOTR）中的安全性和疗效尚不清楚，因为 SOTR 通常由于其不可逆的移植物排斥反应的高风险而被排除在临床研究之外。我们观察到一名患有转移性皮肤鳞状细胞癌的肾移植患者，在使用西普利单抗进行抗肿瘤治疗后出现完全缓解，并通过固定剂量依维莫司预防移植排斥反应。
